Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-06-16
2000-12-12
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514913, A61K 3800
Patent
active
061599417
ABSTRACT:
The invention relates to the use of a somatostatin receptor ligand of nonpeptide origin, e.g. of the general formula Ia or Ib ##STR1## or a pharmaceutically acceptable salt thereof, which has high and/or selective affinity to the somatostatin receptor protein designated SSTR4 and, for the preparation of a medicament for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal. Such conditions are high intraocular pressure (IOP) and/or deep ocular infections. The diseases which may be treated are e.g. glaucoma, stromal keratitis, iritis, retinitis, cataract and conjunctivitis.
REFERENCES:
Mori et al., Neuroscience Letters, vol. 223, pp. 185-188 (1997).
Damour et al., Bioorganic & Medicinal Chemistry Letters, vol. 6, No. 14, pp. 1667-1672 (1996).
Ankersen Michael
Crider Michael Albert
Stidsen Carsten Enggaard
Fay Zohreh
Novo Nordisk A S
Rozek Carol E.
Zelson Steve T.
LandOfFree
Use of somatostatin agonists and antagonists for treating diseas does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of somatostatin agonists and antagonists for treating diseas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of somatostatin agonists and antagonists for treating diseas will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-217090